SEARCH

SEARCH BY CITATION

References

  • 1
    Lok AS, Wilson LA, Thomas HC. Neurotoxicity associated with adenine arabinoside monophosphate in the treatment of chronic hepatitis B virus infection. J. Antimicrob. Chemother. 1984; 14: 939.
  • 2
    Dianzani F. Biological basis for the clinical use of interferon. Gut 1993; 34 (Suppl. 2): S746.
  • 3
    Lok ASF, Wu PC, Lai CL, Leung EKY. Long-term follow-up in a randomised controlled trial of recombinant α2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; ii: 298302.
  • 4
    Wong DKH, Cheung AM, O’Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alfa-interferon treatment in patients with hepatitis B e antigen-positive hepatitis B: Meta-analysis. Ann. Intern. Med. 1993; 119: 31223.
  • 5
    Leung NWY. Liver disease: Significant improvement with lamivudine. J. Med. Virol. 2000; 61: 3805.
  • 6
    Leung N. Management of chronic hepatitis B. Nucleoside analogues in the treatment of chronic hepatitis B. J. Gastroenterol. Hepatol. 2000; 15 (Suppl.): E5360.
  • 7
    De Man RA, Marcellin P, Habal F et al. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. Hepatology 2000; 32: 41317.
  • 8
    McKenzie R, Fried MW, Sallie R et al. Hepatic failure and lactic acidosis due to fialuridine (FIAU), an investigational nucleoside analogue for chronic hepatitis B. N. Engl. J. Med. 1995; 333: 1099105.
  • 9
    Chan HLY, Leung NWY, Hussain M, Wong ML, Lok ASF. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong. Hepatology 2000; 31: 7638.
  • 10
    Gust ID. Epidemiology of hepatitis B infection in the Western Pacific and South East Asia. Gut 1996; 38 (Suppl. 2): S1823.
  • 11
    Hoofnagle JH, Di Bisceglie AM. The treatment of chronic viral hepatitis. N. Engl. J. Med. 1997; 336: 34756.
  • 12
    Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. A preliminary trial of lamivudine for chronic hepatitis B infection. N. Engl. J. Med. 1995; 333: 165761.
  • 13
    Lai CL, Chien RN, Leung NWY et al. A one-year trial of lamivudine for chronic hepatitis B. N. Engl. J. Med. 1998; 339: 618.
  • 14
    Liaw YF, Leung NWY, Chang TT et al. Efficacy and tolerability of two years of lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 2000; 119: 17280.
  • 15
    Leung NWY, Lai CL, Chang TT et al. Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis e antigen seroconversion rates: Results after three years of therapy. Hepatology 2001; 33: 152732.
  • 16
    Chang TT, Lai CL, Liaw YF et al. Enhanced HBeAg seroconversion rates in Chinese patients on lamivudine. Hepatology 1999; 30: 420A (Abstract).
  • 17
    Guan R, Lai CL, Liaw YF et al. Efficacy and safety of 5 years lamivudine treatment of Chinese patients with chronic hepatitis B. J. Gastroenterol. Hepatol. 2001; 16 (Suppl.): A60 (Abstract).
  • 18
    Allen M, Gauthier J, DesLauriers M et al. Two sensitive PCR-based methods for the detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J. Clin. Microbiol. 1999; 37: 333847.
  • 19
    Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999; 30: 56772.
  • 20
    Leung N, Lai CL, Guan R, Liaw YF. The effect of longer duration of harbouring lamivudine resistant hepatitis B virus (YMDD mutants) on liver histology during 3 years lamivudine therapy in Chinese patients. Hepatology 2001; 34: 248A (Abstract).
  • 21
    Villeneuve JP, Condreay LD, Willems B et al. Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B. Hepatology 2000; 31: 20710.
  • 22
    Tsang SW, Chan HL, Leung NW et al. Lamivudine treatment for fulminant hepatic failure due to acute exacerbation of chronic hepatitis B infection. Aliment. Pharmacol. Ther. 2001; 15: 173744.
  • 23
    Locarnini SA, Bartholomeusz A, Delaney WE. Evolving therapies for the treatment of chronic hepatitis B virus infection. Expert Opin. Investig. Drugs 2002; 11: 16987.
  • 24
    Chan HL, Tang JL, Tam W, Sung JJ. The efficacy of thymosin in the treatment of chronic hepatitis B virus infection: a meta-analysis. Aliment. Pharmacol. Ther. 2001; 15: 1899905.